Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics (ARQT) added Dr. Robert Scott, former AbbVie executive, to its board and Nominating and Corporate Governance Committee. He received an option for 20,507 shares and prorated compensation, including equity valued at about $350,000 and cash retainers. The board expanded from 10 to 11 directors.
Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FOR IMMEDIATE RELEASE Arcut is Appoints Rob Scot t, MD to Board of Directors WESTLAKE VILLAGE, Calif., Oct . 28, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-de
Arcutis Biotherapeutics (ARQT) added Rob Scott, MD to its board on Oct. 23, 2026. The move aims to enhance development expertise for ZORYVE and its pipeline, according to the company.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ARQT (Arcutis Biotherapeutics, Inc.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent ARQT coverage spans financial news, technology and corporate actions.
In the last 30 days, ARQT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($127K). The most active reporter was Welgus Howard G. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Board expansion and new director may be viewed as neutral to slightly positive, reflecting governance strengthening.
Board addition may enhance strategic oversight and credibility, modestly supportive for stock.
Board appointment adds development expertise; may modestly support share price.
Analyst upgrade with higher target drives buying interest.
Cantor Fitzgerald initiated coverage of Arcutis Biotherapeutics with an Overweight rating and $48 price target, implying 81.7% upside from Oct 14 close. Analysts highlight Zoryve's strong market position in dermatology and growth potential from diverse indications.
AlphAI scores every news story that mentions ARQT with an AI model for sentiment and relevance, and aggregates insider trades from Arcutis Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Arcutis Biotherapeutics (ARQT) added Dr. Robert Scott, former AbbVie executive, to its board and Nominating and Corporate Governance Committee. He received an option for 20,507 shares and prorated compensation, including equity valued at about $350,000 and cash retainers. The board expanded from 10 to 11 directors.
1 min readArcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FOR IMMEDIATE RELEASE Arcut is Appoints Rob Scot t, MD to Board of Directors WESTLAKE VILLAGE, Calif., Oct . 28, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-de
1 min readArcutis Biotherapeutics (ARQT) added Rob Scott, MD to its board on Oct. 23, 2026. The move aims to enhance development expertise for ZORYVE and its pipeline, according to the company.
1 min readArcutis Biotherapeutics (ARQT) shares rose 12% after Guggenheim raised its price target to $44, citing confidence in 2027 performance. Cantor Fitzgerald also initiated coverage with a $48 target. Revenue is expected to grow from $376M in 2025 to $687M in 2027, though growth is slowing. Management anticipates improved operating leverage in 2027 as sales spending eases.
2 min readCantor Fitzgerald initiated coverage of Arcutis Biotherapeutics with an Overweight rating and $48 price target, implying 81.7% upside from Oct 14 close. Analysts highlight Zoryve's strong market position in dermatology and growth potential from diverse indications.
1 min readViking Therapeutics (VKTX) plans to start a phase 3 trial for its obesity and type 2 diabetes drug, VK2735, in Q4, following mixed phase 2 results. Arcutis Biotherapeutics (ARQT) aims to expand its Zoryve cream's market, with an FDA decision on a new indication expected in early 2027. Both companies have catalysts that could impact their stock prices.
6 min readArcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and long-term topical corticosteroid use at dermatology meetings. The data showed improvements in atopic dermatitis and psoriasis symptoms. ARQT's stock closed at $24.49, up 1.32%, and was up 1.84% in premarket trading.
2 min readArcutis Biotherapeutics presented clinical trial data for ZORYVE cream in infants with eczema, showing 34.4% achieved clear or almost clear skin. The treatment had no serious adverse events. The company also shared data on ZORYVE foam for psoriasis, with 66.4% of patients achieving clear or almost clear scalp skin. Arcutis is seeking FDA approval for ZORYVE cream in infants, with a decision expected in 2027.
2 min readArcutis Biotherapeutics (ARQT) presented data on ZORYVE (roflumilast) at EADV and Fall Clinical Dermatology Conference. The company shared results from the INTEGUMENT-INFANT trial for infants with atopic dermatitis, ARRECTOR and DERMIS-1/2 trials for psoriasis, and collaborative research on seborrheic dermatitis. Additionally, Arcutis presented real-world data on topical corticosteroid use in chronic inflammatory skin conditions.
2 min readJefferies reiterated a Buy rating and $39.00 price target for Arcutis Biotherapeutics (ARQT) due to Zoryve's prescription growth, estimating Q3 2026 sales of $143M. The stock trades at $24.17, below analyst targets. Zoryve's Q3 growth moderated to 8-9% from 13-14% in Q2, with strong margins. Jefferies expects Q4 sales to improve seasonally and forecasts 2026 sales of $525-540M. ARQT reported Q2 2026 revenue of $129.9M, up 59% YoY, and turned profitable.
1 min read
